During the past decade, Asheville Cardiology Associates conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 20 clinical trials were completed, i.e. on average, 117.6% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 14 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Asheville Cardiology Associates" #1 sponsor was "Medtronic Cardiac Rhythm and Heart Failure" with 7 trials, followed by "United Therapeutics" with 5 trials sponsored, "Actelion" with 3 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored and "Bristol-Myers Squibb" with 3 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Asheville Cardiology Associates" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Duke Clinical Research Institute" with 3 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator, "Canadian Heart Research Centre" with 2 trials as a collaborator and "Medtronic" with 2 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "Asheville Cardiology Associates" are "Pulmonary Arterial Hypertension" (7 trials), "Heart Failure" (6 trials), "Coronary Artery Disease" (5 trials), "Atherosclerosis" (2 trials) and "Atrial Fibrillation" (2 trials). Many other conditions were trialed in "Asheville Cardiology Associates" in a lesser frequency.

Most popular intervention types in "Asheville Cardiology Associates" are "Drug" (23 trials), "Device" (12 trials), "Other" (4 trials), "Behavioral" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Empagliflozin" (3 trials), "Apixaban" (2 trials), "Oral treprostinil" (2 trials) and "(BMS/DES)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Asheville Cardiology Associates" are 40 trials for "All" genders.

Currently, there are NaN active trials in "Asheville Cardiology Associates". undefined are not yet recruiting, 1 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Asheville Cardiology Associates, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Asheville Cardiology Associates, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 10 trials that are defined as “Not Applicable".